Thermo Fisher Scientific (NYSE:TMO) Hits New 1-Year High – Here’s What Happened

Shares of Thermo Fisher Scientific Inc. (NYSE:TMO) reached a new 52-week high on Thursday . The stock traded as high as $629.54 and last traded at $629.2060, with a volume of 1346335 shares traded. The stock had previously closed at $621.83.

Analyst Upgrades and Downgrades

TMO has been the subject of a number of research analyst reports. Wall Street Zen downgraded shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a report on Saturday, January 10th. KeyCorp upgraded shares of Thermo Fisher Scientific from a “sector weight” rating to an “overweight” rating and set a $750.00 price target for the company in a research note on Sunday, December 7th. Argus increased their price objective on Thermo Fisher Scientific from $580.00 to $610.00 and gave the company a “buy” rating in a report on Wednesday, October 29th. Hsbc Global Res raised Thermo Fisher Scientific from a “hold” rating to a “strong-buy” rating in a research report on Monday, December 1st. Finally, Morgan Stanley boosted their price objective on Thermo Fisher Scientific from $656.00 to $670.00 and gave the company an “overweight” rating in a research note on Tuesday, December 2nd. One equities research analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $625.47.

Thermo Fisher Scientific Price Performance

The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.11 and a current ratio of 1.50. The stock has a market capitalization of $232.62 billion, a PE ratio of 35.77, a price-to-earnings-growth ratio of 4.11 and a beta of 0.91. The business’s 50-day moving average price is $586.34 and its 200 day moving average price is $523.82.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Wednesday, October 22nd. The medical research company reported $5.79 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.50 by $0.29. Thermo Fisher Scientific had a return on equity of 16.97% and a net margin of 15.02%.The firm had revenue of $11.12 billion during the quarter, compared to the consensus estimate of $10.90 billion. During the same quarter last year, the company posted $5.28 EPS. The company’s revenue for the quarter was up 4.9% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. Research analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Thursday, January 15th. Shareholders of record on Monday, December 15th were paid a dividend of $0.43 per share. The ex-dividend date of this dividend was Monday, December 15th. This represents a $1.72 annualized dividend and a dividend yield of 0.3%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 9.94%.

Thermo Fisher Scientific announced that its board has authorized a stock repurchase program on Thursday, November 6th that allows the company to repurchase $5.00 billion in shares. This repurchase authorization allows the medical research company to repurchase up to 2.4% of its shares through open market purchases. Shares repurchase programs are usually a sign that the company’s leadership believes its stock is undervalued.

Insider Activity at Thermo Fisher Scientific

In related news, VP Lisa P. Britt sold 1,058 shares of the company’s stock in a transaction on Wednesday, November 12th. The shares were sold at an average price of $588.26, for a total transaction of $622,379.08. Following the completion of the sale, the vice president directly owned 13,087 shares in the company, valued at $7,698,558.62. This represents a 7.48% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, COO Michel Lagarde sold 22,046 shares of the firm’s stock in a transaction on Thursday, December 4th. The stock was sold at an average price of $563.56, for a total transaction of $12,424,243.76. Following the completion of the sale, the chief operating officer directly owned 84,117 shares in the company, valued at approximately $47,404,976.52. This trade represents a 20.77% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 149,271 shares of company stock worth $86,507,282 over the last three months. Corporate insiders own 0.33% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. TIAA Trust National Association raised its position in shares of Thermo Fisher Scientific by 10.5% in the 2nd quarter. TIAA Trust National Association now owns 123,948 shares of the medical research company’s stock valued at $50,256,000 after acquiring an additional 11,817 shares during the period. Lombard Odier Asset Management Switzerland SA boosted its position in shares of Thermo Fisher Scientific by 8.4% during the second quarter. Lombard Odier Asset Management Switzerland SA now owns 14,490 shares of the medical research company’s stock worth $5,875,000 after purchasing an additional 1,128 shares in the last quarter. Caledonia Investments PLC increased its position in shares of Thermo Fisher Scientific by 11.5% in the 2nd quarter. Caledonia Investments PLC now owns 111,767 shares of the medical research company’s stock valued at $45,299,000 after buying an additional 11,500 shares in the last quarter. Weaver Capital Management LLC acquired a new stake in Thermo Fisher Scientific during the 3rd quarter worth $506,000. Finally, Heritage Investors Management Corp increased its holdings in shares of Thermo Fisher Scientific by 9.6% in the second quarter. Heritage Investors Management Corp now owns 56,587 shares of the medical research company’s stock worth $22,944,000 after acquiring an additional 4,971 shares in the last quarter. Institutional investors own 89.23% of the company’s stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.